Lower incidence rates of distal large bowel cancer in women when compared with men support the protective role of female hormones. We aimed to determine the associations between hormone replacement therapy, oral contraceptive use, and distal large bowel cancer.
INTRODUCTION
Women have reduced rates of colorectal cancer when compared with men ( 1 ). Epidemiologic studies have shown that exogenous hormones, such as oral contraceptives and hormone replacement therapy, are associated with a lower risk of colorectal cancer ( 2, 3 ) . Th e Women ' s Health Initiative showed that hormone replacement therapy signifi cantly reduces the risk of colorectal cancer ( 4 ) .
Although colorectal cancer is oft en considered a single entity, colon and rectal cancer are in fact distinct disease groups. When comparing colon and rectal cancer of similar stage, there are diff erences in histological diff erentiation, gene expression, and clinical outcomes such as prognosis and survival ( 5, 6 ) . In addition, rectal and distal colonic tumors share similar mutational frequencies, which are different from those observed in proximal colonic tumors ( 7 ) . Th e association between exogenous hormone use and distal large bowel cancer is less well defi ned than the association with colon cancer, although it also seems to be protective ( 8, 9 ) . Previous studies have not incorporated data on women using more contemporary doses of oral contraceptives. Previous work has also lacked the power to analyze racial diff erences in rectal cancer risk associated with hormone replacement therapy or oral contraceptive use.
With data from the North Carolina Colon Cancer Study-II, which is a large population-based case -control study of distal large bowel cancer (defi ned as rectal, recto-sigmoid, or sigmoid cancer), Long et al.
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we aimed to better determine the association of both hormone replacement therapy and oral contraceptive use with the risk of distal large bowel cancer among Caucasian and African-American women in eastern North Carolina.
METHODS

Study cohort
Th e North Carolina Colon Cancer Study-II was a populationbased case -control study of incident distal large bowel cancer (defi ned as rectal, recto-sigmoid, or sigmoid cancer) in Caucasians and African Americans in 33 counties in the central and eastern part of North Carolina. Data for this study were collected by inperson interviews, conducted in the subject ' s home or in another convenient location, by trained nurse interviewers. Measurements of height, weight, and abdominal circumference were obtained when possible. To confi rm the diagnosis of invasive adenocarcinoma of sigmoid, rectosigmoid, or rectum, pathology reports were obtained and reviewed by the study pathologist for each case.
Assessment of distal large bowel cancer cases and controls
Between May 2001 and September 2006, a total of 1,831 potentially eligible patients with a fi rst diagnosis of invasive adenocarcinoma in sigmoid, rectosigmoid, and rectum were identifi ed through the rapid ascertainment system of the North Carolina Central Cancer Registry. Th e procedure for case ascertainment has been described elsewhere ( 10 ) . Cases were eligible for the study if they were residents of the selected counties, were aged between 40 and 80 years, were of African-American or Caucasian race, had a North Carolina driver ' s license or identifi cation card, and were able to complete an interview in English. Of the 1,831 potentially eligible cases identifi ed, 57 (3 % ) were excluded for physician refusal, and 357 (19 % ) were found ineligible. Of the remaining 1,417 eligible cases, 118 (8 % ) were not able to be contacted, 242 (17 % ) refused to participate, and 1,057 (75 % ) completed an in-person interview. Th is population was then limited to women, resulting in 443 female cases of distal large bowel cancer. Th e specifi c response rate for women was not signifi cantly diff erent from the overall response rate, and was not diff erent by race (African-American women 69 % and Caucasian women 71 % ).
Using the technique of randomized recruitment ( 11 ), controls were randomly selected from North Carolina Division of Motor Vehicle records (for controls aged < 65 years) or from Health Care Financing Administration records (for controls aged ≥ 65 years), based on sampling probabilities within blocks defi ned by 5-year age group, sex, and race. Initially, 2,345 subjects were identifi ed as eligible controls, but 518 (22 % ) were later determined to be ineligible. Reasons for exclusion included lack of a North Carolina driver ' s license or identifi cation card (if aged < 65 years), not residing in the ascertainment area of 33 counties, any personal history of colorectal cancer, not speaking English, deaf or hard of hearing, too ill to be interviewed, legally incompetent, or current incarceration. Of the 1,827 eligible controls identifi ed, 325 (18 % ) were not able to be contacted and 483 (26 % ) refused to participate. A total of 1,019 (56 % of eligible controls) completed an interview. Th is population was then limited to women, resulting in 405 controls. Th e specifi c response rate for female controls was similar by race (54 % for African-American women and 56 % for Caucasian women). Among controls, women were slightly less likely to respond than men, but these diff erences were not signifi cant. Th e fi nal data set for analysis included 443 female cases and 405 female controls. Th e study was approved by the institutional review board at the University of North Carolina School of Medicine, and all subjects provided written informed consent.
Assessment of main exposures and other risk factors
We obtained information on hormone replacement therapy, oral contraceptive use, and other reproductive factors during the in-person interview. Participants were asked whether they had ever used hormone replacement therapy, whether they had used these medications within the past year, and the total duration of use at the time of diagnosis (case) or interview (control). Th e same questions were asked with regard to oral contraceptive use. Data on parity, gravidity, age at menarche, menopause, and age at menopause were also obtained. Data on other factors associated with distal large bowel cancer, including nonsteroidal anti-infl ammatory drug (NSAID) use, physical activity, red meat intake, smoking, and family history of colorectal cancer in a fi rst-degree relative, were also included in the interview. Physical activity was assessed through a validated 7-day physical activity recall questionnaire and was measured as a ratio of work metabolic rate to resting metabolic rate, providing an energy expenditure outcome in MET (metabolic equivalent task)-minutes per day ( 12, 13 ) . Dietary intake, including intake of red meat, was assessed through a validated Diet History Questionnaire ( 14, 15 ) . All participants were asked their weight 1 year before diagnosis (case) or interview (control) to calculate body mass index (BMI) from a weight unaff ected by the cancer diagnosis or treatment. Demographic information such as education, marital status, income, and insurance status was also collected.
Statistical analysis
Odds ratios (ORs) and 95 % confi dence intervals (CIs) for the association between hormone replacement therapy and distal large bowel cancer were estimated from unconditional logistic regression models. Hormone replacement therapy use was defi ned as ever use for at least 1 year. All logistic regression models included indicator variables for the matched factors age and race as well as an off set term to adjust for sampling probability ( 11, 16 ) .
Other potential covariates and eff ect-measure modifi ers assessed for inclusion in multivariable models were: years of education (below high school, high school / GED (General Education Development), or above high school), annual household income ( < $ 25,000 or ≥ $ 25,000), smoking status (ever > 100 cigarettes or never), marital status (married, previously married, or never married), insurance status (any or none), gravidity (0, 1 -3, and > 3 pregnancies), BMI calculated from weight measured 1 year previously in kg / m 2 ( < 25 normal / underweight, 25 -30 overweight, and ≥ 30 obese), menopausal status (yes or no), oral contraceptive use (ever or never), family history of colon cancer in a fi rst-degree relative (yes or no), physical activity measured in MET-min / day Exogenous Hormone Use and Distal Large Bowel Cancer COLON/SMALL BOWEL (in quartiles), red meat consumption (total intake of luncheon meats, beef, pork, lamb, and organ meats (g / day), continuous), and regular NSAID use (any NSAID > 3 times a week for at least 3 months, yes or no). Presence of a previous colorectal polyp was thought to be an intermediate step on the causal pathway to distal large bowel cancer; therefore, this variable was not included as a covariate in the analyses.
Interaction between the main exposure and each covariate was fi rst assessed through likelihood ratio testing using a signifi cance level of 0.10. No signifi cant eff ect-measure modifi ers were identifi ed. To determine what covariates should be entered in the fi nal multivariable models, we constructed a full model with all potential confounders, and assessed the change in β -coeffi cients for hormone replacement therapy users vs. nonusers in relation to distal large bowel cancer when covariates were removed. Indicator variables for the strata of matched factors were retained in the model (age, race, and a sampling probability off set term). Covariates were removed from the model using a backward elimination technique using a threshold of < 10 % change in β -coeffi cients. Th e fi nal model with hormone replacement therapy as the main exposure contained the outcome, exposure, educational level, smoking status, BMI, family history of colon cancer, oral contraceptive use, menopausal status, physical activity, red meat consumption, and NSAID use.
Th e above modeling technique was repeated with oral contraceptive use as the main exposure. Th e fi nal model contained the outcome, exposure, educational level, smoking status, BMI, family history of colon cancer, hormone replacement therapy use, menopausal status, physical activity, red meat consumption, and NSAID use.
Th e eff ects of duration of use of both hormone replacement therapy and oral contraceptive use, each divided into quartiles, were also evaluated through logistic regression models with nonuse of hormone replacement therapy or nonuse of oral contraceptives, respectively, as the reference category. Th e data set was then stratifi ed by race to determine the eff ects of ever vs. never use of hormone replacement therapy or oral contraceptives in Caucasians and African Americans. Th e above modeling technique was repeated within each stratum of race for each main exposure.
Finally, a polytomous logistic regression model was used to determine the site-specifi c (rectal, recto-sigmoid, and sigmoid) eff ects of ever use of hormone replacement therapy or oral contraceptives. Because polytomous models cannot incorporate weights, the off set term was not included for these analyses. A similar backward elimination strategy based on < 10 % change in β -coeffi cients was used in these analyses. For all analyses, P values were two sided, and a P value of ≤ 0.05 was considered statistically significant. All statistical analyses were performed using Stata version 9.0 (Texas Station, TX). Table 1 presents the baseline characteristics of the study population according to case or control status. For hormone replacement therapy, a signifi cantly smaller percentage of cases than controls reported ever use of these agents. For the main exposure of oral contraceptive use, similar percentages of both cases and controls reported ever use. With regard to other characteristics of the population, the cases were slightly younger, had a higher BMI, and were less educated. A slightly higher percentage of the cases were African Americans, fewer reported regular use of NSAIDS, and cases consumed more red meat. It is noteworthy that the populations were quite similar with regard to reproductive characteristics such as age of onset of menses, gravidity, parity, and age of onset of menopause. Similar percentages in both groups were menopausal.
RESULTS
Ever use of hormone replacement therapy was associated with a reduced risk of distal large bowel cancer in our multivariate analysis (OR 0.52, 95 % CI 0.38 -0.73; Table 2 ). Increased duration of use was associated with a further reduction in distal large bowel cancer incidence. For women with < 4 years of use, the ORs for distal large bowel cancer was 0.77 (95 % CI 0.44 -1.35). For each quartile of hormone replacement therapy use, the ORs for distal large bowel cancer continued to decrease. Th e highest quartile of use, ≥ 15 years, had an OR of 0.34 (95 % CI 0.20 -0.58) for incident distal large bowel cancer ( P for trend < 0.001; Table 3 ). When sitespecifi c locations of the cancer were evaluated as the outcome, hormone replacement therapy reduced the risk of distal large bowel cancer in all three locations, with signifi cant eff ects in the sigmoid and rectum ( Table 4 ) .
Ever use of oral contraceptives was not associated with a reduction in distal large bowel cancer incidence in our multivariate analysis (OR 0.95, 95 % CI 0.67 -1.34; Table 5 ). Th ere was no change in the association based on duration of use. Women with short-term use (0 -2 years) had an OR of 0.63 (95 % CI 0.38 -1.03) for distal large bowel cancer when compared with nonusers. With increasing duration of use, there was a slight increase in the odds of distal large bowel cancer, although this was not signifi cant ( P for trend 0.217; Table 6 ). Th ere was no diff erence in the eff ect of oral contraceptives based on rectal, recto-sigmoid, or sigmoid cancer location ( Table 7 ) . We also stratifi ed our analyses by age. Interestingly, there was a nonsignifi cant reduction in the risk of distal large bowel cancer in the oldest age group of women who reported previous use of oral contraceptive agents ( ≥ 70 years; OR 0.52, 95 % CI 0.24 -1.15).
Th e multivariate analyses of ever use of hormone replacement therapy or oral contraceptives and incident distal large bowel cancer were repeated within strata of race. Th ere were no diff erences in the eff ects of these medications by Caucasian or AfricanAmerican ethnicity.
DISCUSSION
In this population-based case -control study, we observed a signifi cant protective eff ect of hormone replacement therapy for incident distal large bowel cancer. Increasing duration of use seemed to convey further reduction in distal large bowel cancer risk. Th is reduction in risk was evident for both Caucasians and African Americans and in site-specifi c locations of the cancer. ). e Regular NSAID use defi ned as > 3 times a week for a period of at least 3 months. f Family history of colorectal cancer in the fi rst-degree relative. g Red meat consumption calculated from luncheon meats, beef, pork, lamb, and organ meats over 1 year before interview or diagnosis of rectal cancer.
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h Physical activity in MET-min / day from a validated 7-day physical activity recall questionnaire.
Exogenous Hormone Use and Distal Large Bowel Cancer
COLON/SMALL BOWEL tive eff ect of hormone replacement therapy ( 17 -19 ) . However, a recent examination of combined data from the WHI clinical trial and observational study did not provide evidence of a clinically important benefi t of hormone replacement therapy on the incidence of colorectal cancer of over 7 to 8 years of treatment and follow-up ( 20 ) . Th e relationship of these medications with distal large bowel (specifi cally rectal) cancer has also been evaluated, again with mixed conclusions. Many of these studies showed a protective eff ect, but did not reach statistical signifi cance ( 21 -27 ) . Other studies found nonsignifi cantly elevated ORs for the eff ect ( 28 -30 ). Nichols et al. ( 31 ) did fi nd a signifi cant protective eff ect of hormone replacement therapy for rectal cancer in their population-based case -control study in Wisconsin. Grodstein et al. ( 9 ) performed a meta-analysis of the role of hormone replacement therapy in the development of rectal cancer and obtained an OR of 0.81 (95 % CI 0.72 -0.92). Our result is consistent with this protective eff ect. Other studies have also analyzed whether there is a dose-response trend for the use of hormone replacement therapy, and have not shown increased protection with increased duration of use ( 26 ) . Our study did fi nd further reduction in distal large bowel cancer incidence with prolonged duration of use. To our knowledge, no previous study has stratifi ed analyses of hormone replacement therapy and distal large bowel cancer according to race. We found no diff erence in the eff ect based on Caucasian or African-American ethnicity.
Oral contraceptives have also been studied with regard to colorectal cancer risk. Two meta-analyses found a mild protective eff ect for ever vs. never use (OR of 0.8) ( 3, 32 ) . One of these analyses found the eff ect to be most pronounced for recent users of oral contraceptives (OR 0.46, 95 % CI 0.30 -0.71) ( 3 ). In contrast to these studies, we found no risk reduction for incident distal large bowel cancer by oral contraceptives. Results of previous studies of oral contraceptive use and rectal cancer have been mixed, many have shown a trend toward a mild protective eff ect, but have not reached statistical signifi cance ( 3 ) . Th e only meta-analysis that specifi cally evaluated oral contraceptive use and rectal cancer yielded an OR of 0.74 (95 % CI 0.59 -0.93) ( 3 ) . Several studies in this meta-analysis were published in the 1980s and may have disproportionately contained women who used higher-dose estrogen formulations than are predominantly used today. Higher-dose formulations of oral contraceptives were prevalent before 1976 ( 33 ) . Th e lack of a protective eff ect observed in our study may be because modern-day formulations of oral contraceptives contain very low doses of estrogen and progesterone (between 20 and 35 mcg of Oral contraceptive use was not protective for the development of distal large bowel cancer, regardless of the duration of use, race, or site-specifi c location of the cancer.
Previous studies have evaluated the relationship between hormone replacement therapy and colorectal cancer. Although there seems to be an overall protective eff ect, some studies have failed to yield a reduction in incidence of colorectal cancer. Randomized controlled trial data from the Women ' s Health Initiative (WHI) show a protective eff ect (hazard ratio 0.63, 95 % CI 0.43 -0.92) of combined estrogen-and progesterone-containing hormone replacement therapy for colorectal cancer ( 4 ). In addition, several observational studies of colorectal adenomas have shown a protec- Long et al.
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ethinyl estrodiol compared with ≥ 50 mcg). We performed additional analyses supporting this hypothesis that showed a trend for risk reduction in the oldest strata of women, who would likely have been exposed to higher doses of estrogen and progesterone containing oral contraceptives. Some forms of oral contraceptives used today are also progestin-only, although traditionally progestin-only users represent a very small proportion of overall users ( 33 ) . Our study population was accrued between 2001 and 2006, and the average age of women in our study was approximately 63 years. Th ese women may therefore represent a mixed population of both high-and low-dose oral contraceptive users, which may explain our lack of an association. Even in previous studies in which a protective eff ect was found, oft en there was no doseresponse trend with increased duration of use ( 2, 3, 31 ) . Th is lack of a dose-response eff ect with oral contraceptives argues against a substantial causative risk reduction. Th e mechanism behind the association between exogenous hormone therapy and distal large bowel cancer is uncertain. Female hormones may protect against cancers of the large bowel as a result of changes in bile synthesis and secretion. Th is can result in reduced concentration of bile acids in the colon ( 34 ) . Other biological mechanisms have been proposed, including the potential inhibition of colon cancer cells by estrogen ( 35 ) and the reduction of serum insulin-like growth factor ( 36 ) . Recently, it has also been proposed that progesterone may enhance the inhibitory eff ect of estrogen on colon cancer cells ( 37 ) . Newcomb et al. ( 37 ) performed a case -control study in which pathology from cases was tested for microsatellite instability (MSI). For women with MSIlow or MSI-stable tumors, there was a signifi cant (40 % ) reduction in colorectal cancer risk associated with combined estrogen -progesterone hormone replacement therapy use. In contrast, no association was found with MSI-high tumors. Additional data show that estrogen exposure in women may protect against MSI, and the lack of estrogen in older women increases the risk of unstable tumors ( 38 ) . Rates of MSI diff er between proximal and distal location of the tumor. Slattery et al. ( 7 ) found MSI in 23.7 % of proximal and only 3.8 % of distal and 2.0 % of rectal tumors. Although it is unknown whether the mechanism of action of female hormones diff ers based on proximal vs. distal location of the cancer, our data support that the protection continues in the distal large bowel.
Th ere were many strengths of this study, including a large sample size, the in-person data collection, the confi rmation of pathology by a study pathologist, and the ability to control for many risk factors. Th e associations between exposures and distal large bowel cancer were similar to other studies of distal large bowel cancer suggesting external validity. For example, the distal large bowel cancer cases in our study had a signifi cantly greater BMI, consumed more red meat, and also used NSAIDS less frequently. Th ese risk factors are consistently observed throughout the literature in association with distal large bowel (specifi cally rectal) cancer ( 39 -42 ) . Th ere were also several limitations to this population-based case -control study. First, use of hormone replacement therapy and oral contraceptives was by self-report. Certainly, there is potential for recall bias with any self-reported data. However, previous studies have shown good agreement between self-report of hormone replacement therapy and medical records ( 43 -45 ) . Although we did have information on whether women had used hormone replacement therapy within 1 year before diagnosis, we did not have information on time since their last dose to determine whether the eff ect diminished over time. Specifi cally, this study cannot answer the question of whether or not there is a rebound increase in risk of distal large bowel cancer aft er withdrawal of these medications or continued protection aft er the medication is discontinued. It has also been previously argued that women who use oral contraceptives and hormone replacement therapy represent " healthy users " ( 46 ) . Th is healthy-user eff ect could contribute to the protective association that we found. However, in an attempt to account for this, we statistically controlled for many associated risk factors for distal large bowel cancer, including socioeconomic status information and dietary consumption patterns. Finally, specifi c formulations and dosages of hormone replacement therapy and oral contraceptives were not available within our data set. Specifi c doses of estrogen or progesterone may have diff ering eff ects on the risk of distal large bowel cancer. Our work on hormone replacement therapy is important in that it shows a protective dose-response eff ect for distal large bowel cancer with increased duration of use. Aft er publication of the results from the WHI, there has been a decline in overall prescriptions for hormone replacement therapy in the United States and in United Kingdom ( 47, 48 ) . In fact, hormone therapy prescribing has fallen by approximately 50 % since 2002 ( 49 ) . It remains to be observed whether alterations in prescribing patterns for these medications may aff ect the incidence of distal large bowel cancer. Much of the reduced incidence of distal large bowel cancer observed in the past two decades may have been partially related to long-term hormone replacement therapy use that is no longer recommended based on the risk -benefi t ratio observed in the WHI ( 4 ). However, women continue to use hormone replacement therapy for short-term perimenopausal symptom control ( 50, 51 ) . If practice patterns permanently change from long-term use to short-term perimenopausal use, further work is necessary to characterize the duration of distal large bowel cancer risk reduction associated with these medications. Studies have found that former users of hormone replacement therapy do not retain the protective eff ects ( 17 ). Grodstein et al. ( 26 ) showed that the risk reduction observed with hormone replacement therapy disappears at approximately 5 years aft er cessation of these medications. Further work should evaluate women aft er cessation of these medications to determine whether there is a " rebound " eff ect of an increase in polyp formation. It may become important in the future to tailor timing of women ' s colorectal screening based on cessation of hormone replacement therapy.
In conclusion, this study suggests that women who use hormone replacement therapy are at a reduced risk of developing distal large bowel cancer, regardless of race. Longer duration of use is associated with increased protection. It is possible that widespread use of hormone replacement therapy is partially responsible for the reductions that we have observed in distal large bowel cancer incidence over time.
